Clinical Trial Innovation
N.1 maintains a clinical/translational team that facilitates IRB/DSRB filings and assists with regulatory considerations with a particular focus on interventional studies. The Institute also maintains an advisory team of clinicians, engineers, and industry leaders to address Institute objectives ranging from clinical acceleration to compliance.
Theodore Kee, M.S.
Head of Clinical Trials, N.1 Labs @N.1
Theodore Kee holds a M.S. in Bioengineering from UCLA, and he is the head of clinical trials at N.1 Labs at the N.1 Institute for Health (N.1). Theodore has successfully obtained protocol approvals for seven first-in-human interventional clinical studies. Currently, he conducts research with Prof. Ho and coordinates the group's clinical trials nanodiamonds for enhanced therapeutic delivery and imaging, and a phenotypic personalized medicine (PPM) platform, termed CURATE.AI, that optimizes already given therapy regimens and develops novel therapeutic combinations for a myriad of indications, including oncology. Theodore has earned numerous accolades including being named finalist in both NIH DEBUT Challenge and ASAIOfyi.
***CLINICAL STUDY INQUIRIES***: Please contact Theodore Kee at bietwk AT nus.edu.sg. Thank you.